Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study

INTRODUCTION: STRIVE was a 4-year, multicenter, observational, open-label, single-arm study of natalizumab treatment in anti-JC virus antibody-negative (JCV-negative) relapsing-remitting multiple sclerosis (RRMS) patients with disease duration ≤ 3 years. The objective of STRIVE was to examine no evi...

Descripción completa

Detalles Bibliográficos
Autores principales: Perumal, Jai, Balabanov, Roumen, Su, Ray, Chang, Roger, Balcer, Laura, Galetta, Steven, Campagnolo, Denise I., Avila, Robin, Lee, Lily, Rutledge, Danette, Fox, Robert J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8279996/
https://www.ncbi.nlm.nih.gov/pubmed/34014549
http://dx.doi.org/10.1007/s12325-021-01722-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8279996/
https://www.ncbi.nlm.nih.gov/pubmed/34014549
http://dx.doi.org/10.1007/s12325-021-01722-w

Ejemplares similares